Effect of protein binding on the pharmacokinetics of the six substrates in the Basel phenotyping cocktail in healthy subjects and patients with liver cirrhosis

• Published in: European journal of pharmaceutical sciences Vol. 202; p. 106885
• Main Authors: Duthaler, Urs, Chapuisat, Fabio, Hanimann, Robin, Krähenbühl, Stephan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2024
• Subjects: Basel phenotyping cocktail; CYP1A2; CYP2B6; CYP2C19; CYP2C9; CYP2D6; CYP3A4; Protein binding; Basel phenotyping cocktail; CYP2C9; CYP2B6; CYP2D6; CYP1A2; CYP2C19; CYP3A4; Protein binding
• DOI: 10.1016/j.ejps.2024.106885
• ISSN: 0928-0987; 1879-0720

•In control subjects and patients with liver cirrhosis, the metabolic ratios (MR) calculated with total or free drug concentrations correlated well for probe drugs with protein binding ≤99 %.•CYP activity was predicted well by the MR calculated with free or total concentrations of probe drugs with protein binding ≤99 %.•For probe drugs with protein binding >99 %, CYP activity may be predicted better using free drug concentrations for MR calculation.•To avoid problems with protein binding, probe drugs with protein binding ≤99 % should be preferred for phenotyping. Phenotyping serves to estimate enzyme activities in healthy persons and patients in vivo. Low doses of enzyme-specific substrates are administered, and activities estimated using metabolic ratios (MR, calculated as AUCmetabolite/AUCparent). We administered the Basel phenotyping cocktail containing caffeine (CYP1A2 substrate), efavirenz (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6) and midazolam (CYP3A) to 36 patients with liver cirrhosis and 12 control subjects and determined free and total plasma concentrations over 24 h. Aims were to assess whether MRs reflect CYP activities in patients with liver cirrhosis and whether MRs calculated with free plasma concentrations (MRfree) provide better estimates than with total concentrations (MRtotal). The correlation of MRtotal with MRfree was excellent (R2 >0.910) for substrates with low (<30 %, caffeine and metoprolol) and intermediate protein binding (≥30 and <99 %, midazolam and omeprazole) but weak (R2 <0.30) for substrates with high protein binding (≥99 %, efavirenz and flurbiprofen). The correlations between MRtotal and MRfree with CYP activities were good (R2 >0.820) for CYP1A2, CYP2C19 and CYP2D6. CYP3A4 activity was reflected better by midazolam elimination than by midazolam MRtotal or MRfree. The correlation between MRtotal and MRfree with CYP activity was not significant or weak for CYP2B6 and CYP2C9. In conclusion, MRs of substrates with an extensive protein binding (>99 %) show high inter-patient variabilities and do not accurately reflect CYP activity in patients with liver cirrhosis. Protein binding of the probe drugs has a high impact on the precision of CYP activity estimates and probe drugs with low or intermediate protein binding should be preferred. [Display omitted]